$ACAD
ACADIA PHARMACEUTICALS INC

2013 Q4 Form 10-Q Financial Statement

#000119312513430089 Filed on November 06, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $37.00K $240.0K $3.478M
YoY Change -90.26% -93.1% 495.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.300M $3.800M $1.500M
YoY Change 86.96% 153.33% 0.0%
% of Gross Profit
Research & Development $7.900M $7.254M $4.400M
YoY Change 61.22% 64.86% 5.82%
% of Gross Profit
Depreciation & Amortization $40.00K $40.00K $30.00K
YoY Change 100.0% 33.33% 0.0%
% of Gross Profit
Operating Expenses $12.20M $11.05M $5.885M
YoY Change 69.44% 87.78% 3.66%
Operating Profit -$10.81M -$2.407M
YoY Change 349.15% -52.74%
Interest Expense $100.0K $116.0K $5.000K
YoY Change 2220.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.00M -$10.70M -$2.400M
YoY Change 76.47% 345.83% -52.94%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.05M -$10.70M -$2.402M
YoY Change 76.93% 345.25% -52.68%
Net Earnings / Revenue -32564.86% -4456.25% -69.06%
Basic Earnings Per Share
Diluted Earnings Per Share -$131.9K -$119.6K -$44.53K
COMMON SHARES
Basic Shares Outstanding 90.87M shares 88.78M shares 53.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $185.8M $196.2M $23.10M
YoY Change 72.08% 749.26% -36.19%
Cash & Equivalents $11.71M $11.80M $8.016M
Short-Term Investments $174.1M $184.4M $15.00M
Other Short-Term Assets $1.800M $2.500M $600.0K
YoY Change 200.0% 316.67% 0.0%
Inventory
Prepaid Expenses $1.820M
Receivables
Other Receivables
Total Short-Term Assets $188.4M $198.7M $23.69M
YoY Change 73.53% 738.82% -35.64%
LONG-TERM ASSETS
Property, Plant & Equipment $579.0K $490.0K $63.00K
YoY Change 1278.57% 677.78% -68.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $179.0K $120.0K $2.000K
YoY Change 5900.0% -98.0%
Total Long-Term Assets $758.0K $610.0K $65.00K
YoY Change 1704.76% 838.46% -67.5%
TOTAL ASSETS
Total Short-Term Assets $188.4M $198.7M $23.69M
Total Long-Term Assets $758.0K $610.0K $65.00K
Total Assets $189.1M $199.3M $23.75M
YoY Change 74.16% 739.09% -35.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $372.0K $1.120M $1.131M
YoY Change -72.95% -0.97% -13.0%
Accrued Expenses $6.552M $6.670M $4.686M
YoY Change 58.3% 42.34% 6.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $6.979M $7.870M $6.086M
YoY Change 17.33% 29.31% -4.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $10.70M $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $8.000K $2.000K $0.00
YoY Change -99.95% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.979M $7.870M $6.086M
Total Long-Term Liabilities $8.000K $2.000K $0.00
Total Liabilities $6.987M $7.872M $6.086M
YoY Change 17.47% 29.35% -31.62%
SHAREHOLDERS EQUITY
Retained Earnings -$405.7M -$393.6M -$360.9M
YoY Change 10.32% 9.06%
Common Stock $9.000K $9.000K $6.000K
YoY Change 28.57% 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $182.1M $180.8M $17.66M
YoY Change
Total Liabilities & Shareholders Equity $189.1M $199.3M $23.75M
YoY Change 74.16% 739.09% -35.81%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$12.05M -$10.70M -$2.402M
YoY Change 76.93% 345.25% -52.68%
Depreciation, Depletion And Amortization $40.00K $40.00K $30.00K
YoY Change 100.0% 33.33% 0.0%
Cash From Operating Activities -$10.27M -$9.470M -$5.310M
YoY Change 63.28% 78.34% 27.34%
INVESTING ACTIVITIES
Capital Expenditures -$130.0K -$430.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $9.670M -$3.520M -$2.740M
YoY Change -127.58% 28.47% -161.16%
Cash From Investing Activities $9.550M -$3.950M -$2.740M
YoY Change -127.24% 44.16% -161.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 630.0K 970.0K 6.860M
YoY Change -99.31% -85.86% -68700.0%
NET CHANGE
Cash From Operating Activities -10.27M -9.470M -5.310M
Cash From Investing Activities 9.550M -3.950M -2.740M
Cash From Financing Activities 630.0K 970.0K 6.860M
Net Change In Cash -90.00K -12.45M -1.190M
YoY Change -100.18% 946.22% -496.67%
FREE CASH FLOW
Cash From Operating Activities -$10.27M -$9.470M -$5.310M
Capital Expenditures -$130.0K -$430.0K
Free Cash Flow -$10.14M -$9.040M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
90866470 shares
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8016000
CY2013Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.38
CY2013Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1855637 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
88972357 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
1855637 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88972357 shares
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7870000
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
84000
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1410000
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
210000
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
574280000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1120000
CY2013Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
446000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
180754000
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-393619000
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
80000
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
10659000
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6670000
CY2013Q3 us-gaap Liabilities
Liabilities
7872000
CY2013Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
9000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
199285000
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120000
CY2013Q3 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
184377000
CY2013Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
184377000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
490000
CY2013Q3 us-gaap Assets
Assets
199285000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11803000
CY2013Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
184297000
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
20300000
CY2013Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
193621000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2495000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
198675000
CY2013Q3 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
4604000
CY2013Q3 acad Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
105000
CY2013Q3 acad Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
25000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6889000
CY2012Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5347137 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73334216 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5347137 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73334216 shares
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5948000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
413000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
452693000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1375000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
364000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
84984000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367720000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
434000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
17658000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4139000
CY2012Q4 us-gaap Liabilities
Liabilities
5948000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108590000
CY2012Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
56382000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
50068000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2012Q4 us-gaap Assets
Assets
108590000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57899000
CY2012Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56382000
CY2012Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
107598000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
581000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
108548000
CY2012Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
3216000
CY2012Q4 acad Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
5000
CY2012Q4 acad Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
5000
dei Trading Symbol
TradingSymbol
ACAD
dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001070494
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
51589000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21504000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83946000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10725000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
490000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
80000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
120000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
186756000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
234000
us-gaap Revenues
Revenues
1108000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1914000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25819000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
10000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26133000
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
80000
us-gaap Net Income Loss
NetIncomeLoss
-25899000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-938000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
111053000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8444000
us-gaap Share Based Compensation
ShareBasedCompensation
3537000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-46096000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-135645000
us-gaap Operating Expenses
OperatingExpenses
27241000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-354000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2531000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-255000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
111053000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Depreciation
Depreciation
88000
us-gaap Depreciation
Depreciation
40000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18797000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15336000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53262000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11502000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-12000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
15609000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
28000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Revenues
Revenues
4527000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-274000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
28000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14044000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
252000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14067000
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-4000
us-gaap Net Income Loss
NetIncomeLoss
-14039000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
161000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6939000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4701000
us-gaap Share Based Compensation
ShareBasedCompensation
1379000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1127000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
9526000
us-gaap Operating Expenses
OperatingExpenses
18594000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2990000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1182000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-829000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6967000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
252000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
24883000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13893000
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9200000 shares
CY2013Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107900000
CY2013Q3 acad Stock Issued During Period Shares Stock Warrants Exercised
StockIssuedDuringPeriodSharesStockWarrantsExercised
1643006 shares
CY2013Q3 acad Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
1759162 shares
CY2012 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5347137 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53911000 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11919000 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2012Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5000
CY2012Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2012Q3 us-gaap Revenues
Revenues
3478000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2400000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2407000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2402000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1485000
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
488000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
5885000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4400000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89504000 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10523000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
110000
CY2013Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
116000
CY2013Q3 us-gaap Revenues
Revenues
240000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10585000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10811000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-10695000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3797000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1900000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
11051000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7254000

Files In Submission

Name View Source Status
0001193125-13-430089-index-headers.html Edgar Link pending
0001193125-13-430089-index.html Edgar Link pending
0001193125-13-430089.txt Edgar Link pending
0001193125-13-430089-xbrl.zip Edgar Link pending
acad-20130930.xml Edgar Link completed
acad-20130930.xsd Edgar Link pending
acad-20130930_cal.xml Edgar Link unprocessable
acad-20130930_def.xml Edgar Link unprocessable
acad-20130930_lab.xml Edgar Link unprocessable
acad-20130930_pre.xml Edgar Link unprocessable
d597060d10q.htm Edgar Link pending
d597060dex101.htm Edgar Link pending
d597060dex311.htm Edgar Link pending
d597060dex312.htm Edgar Link pending
d597060dex321.htm Edgar Link pending
d597060dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending